|
Company:
|
GERON CORP (GERN)
|
|
Form Type:
|
SC 13G/A
|
|
Filing Date:
|
2/17/1998
|
|
CIK:
|
0000886744
|
|
Address:
|
919 EAST HILLSDALE BOULEVARD
SUITE 250
|
|
City, State, Zip:
|
FOSTER CITY, California 94404
|
|
Telephone:
|
(650) 473-7700
|
|
Fiscal Year:
|
12/31
|
|
|
|
|
|
Last Trade
|
Last Trade:
$2.42
|
Change:
-0.04 (-1.63%)
|
Trade Time:
Aug 05
|
Market Cap:
$913.42M
|
|
|
|
|
|
|
Description of Business
|
|
Geron is a late-stage clinical biopharmaceutical company that is focused on the
development and potential commercialization of imetelstat, a first-in-class
telomerase inhibitor. Geron's vision is to become a leader in the treatment of
blood cancers, or hematologic malignancies, and is committed to improving and
extending the lives of patients by changing the course of these diseases by
targeting telomerase. We believe data from our prior Phase 2 clinical trials
provide strong evidence that imetelstat targets telomerase to inhibit the
uncontrolled proliferation of malignant stem and progenitor cells enabling
recovery of bone marrow and normal blood cell production, which indicate
potential disease-modifying activity. We believe this potential disease
modification may differentiate imetelstat from other currently approved and
investigational treatments in myeloid hematologic malignancies.
|
|
|
|